PHAXIAM Therapeutics Management

Management Kriterienprüfungen 1/4

PHAXIAM Therapeutics' CEO is Thibaut Fayet, appointed in Jun 2023, has a tenure of 1.42 years. total yearly compensation is €391.73K, comprised of 34.5% salary and 65.5% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth €9.13K. The average tenure of the management team and the board of directors is 1.4 years and 11.5 years respectively.

Wichtige Informationen

Thibaut Fayet

Geschäftsführender

€391.7k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	34.5%
Amtszeit als Geschäftsführer	1.4yrs
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	1.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Thibaut Fayet im Vergleich zu den Einnahmen von PHAXIAM Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

Vergütung im Vergleich zum Markt: Thibaut's total compensation ($USD427.46K) is above average for companies of similar size in the French market ($USD326.18K).

Entschädigung vs. Einkommen: Insufficient data to compare Thibaut's compensation with company performance.

Geschäftsführer

Thibaut Fayet (56 yo)

1.4yrs

Amtszeit

€391,725

Vergütung

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 9.1k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 629.8
Frédéric Mathat	Chief Financial Officer	less than a year	keine Daten	keine Daten
Cindy Fevre	Chief Scientific Officer	1.8yrs	keine Daten	keine Daten
Naomi Eichenbaum	Director Investor Relations	no data	keine Daten	keine Daten
Pascal Birman	Chief Medical Officer	1.4yrs	keine Daten	keine Daten
Philip Lorenzi	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten
Eric Raymond	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten
Bridget Bax	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten
Arthur Frankel	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten
Kurt Gunter	Consultant & Member of Scientific Board	no data	keine Daten	keine Daten

1.4yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: PHXM's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	keine Daten	keine Daten
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	keine Daten	keine Daten
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	keine Daten	keine Daten
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	keine Daten	keine Daten
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	keine Daten	keine Daten
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.7k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 804.8
Hilde Windels	Independent Director	10.2yrs	€56.75k	keine Daten
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	keine Daten
Leila Nicolas	Representative Director	1.4yrs	€26.25k	keine Daten
Robert Sebbag	Independent Director	1.4yrs	€21.75k	keine Daten
Valerie Faillat	Independent Director	less than a year	keine Daten	keine Daten

11.5yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: PHXM's board of directors are seasoned and experienced ( 11.5 years average tenure).

PHAXIAM Therapeutics Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Price target decreased to €5.80

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Analysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long

Price target decreased to €14.50

Consensus forecasts updated

Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

Analysts update estimates

Earnings beat expectations, revenue disappoints

New 90-day low: €6.63

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years

New 90-day high: €8.88

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?

New 90-day high: €8.02

New 90-day high: €6.50

Analysts update estimates

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.24

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.95

New 90-day low - €5.51

New 90-day low - €6.06

New 90-day low - €6.74

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder